Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695)

Authors: Flaig, Thomas W., Tangen, Catherine M., Daneshmand, Siamak, Alva, Ajjai Shivaram, Lucia, M. Scott, McConkey, David James, Theodorescu, Dan, Goldkorn, Amir, Milowsky, Matthew I., Bangs, Rick, MacVicar, Gary R., Bastos, Bruno R., Fowles, Jared S., Gustafson, Daniel L., Plets, Melissa, Thompson, Ian M., Lerner, Seth P.

Source: European urology. 84(3):341-347

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100195205337.0x000001&indx=1&recIds=ETOCvdc_100195205337.0x000001

Disparities in Access to Novel Systemic Therapies in Patients With Urinary Tract Cancer: Propagating Access, Policies and Resources Uniformly

Authors: Necchi, Andrea, Joshi, Monika, Bangs, Rick, Makaroff, Lydia, Grivas, Petros, Kamat, Ashish M., Kassouf, Wassim, Raggi, Daniele, Marandino, Laura, Krupski, Tracey, Flaig, Thomas W., Spiess, Philippe E.

Source: Clinical genitourinary cancer. 21(2):301-308

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100186085837.0x000001&indx=1&recIds=ETOCvdc_100186085837.0x000001

Phase 2 Trial of Atezolizumab in Bacillus Calmette-Guérin–unresponsive High-risk Non–muscle-invasive Bladder Cancer: SWOG S1605

Authors: Black, Peter C., Tangen, Catherine M., Singh, Parminder, McConkey, David J., Lucia, M. Scott, Lowrance, William T., Koshkin, Vadim S., Stratton, Kelly L., Bivalacqua, Trinity J., Kassouf, Wassim, Porten, Sima P., Bangs, Rick, Plets, Melissa, Thompson, Ian M., Jr, Lerner, Seth P.

Source: In European Urology December 2023 84(6):536-544

Improving Patient Advocacy in NCI Scientific Steering Committees and Task Forces

Authors: Bangs, Rick, Lynn, Jean M, Obot, Evelyn, Osborne, Sherill, Norris, Kim

Source: Journal of the National Cancer Institute. 114(8):1059-1064

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100157403386.0x000001&indx=1&recIds=ETOCvdc_100157403386.0x000001

TrueNTH Sexual Recovery Intervention for couples coping with prostate cancer: Randomized controlled trial results

Authors: Wittmann, Daniela, Mehta, Akanksha, Bober, Sharon L., Zhu, Ziwei, Daignault‐Newton, Stephanie, Dunn, Rodney L., Braun, Thomas M., Carter, Caroline, Duby, Ashley, Northouse, Laurel L., Koontz, Bridget F., Glodé, L. Michael, Brandon, Jan, Bangs, Rick, McPhail, John, McPhail, Susan, Arab, Lenore, Paich, Kellie, Skolarus, Ted A., An, Lawrence C., Nelson, Christian J., Saigal, Christopher S., Chen, Ronald C., Mulhall, John P., Hawley, Sarah T., Hearn, Jason W. D., Spratt, Daniel E., Pollack, Craig E.

Source: Cancer. 128(7):1513-1522

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100144654359.0x000001&indx=1&recIds=ETOCvdc_100144654359.0x000001

A phase III randomized trial of eribulin (E) with gemcitabine vs standard of care (SOC) for patients (pts) with metastatic urothelial carcinoma (mUC) refractory to or ineligible for PD/PDL1 antibody (Ab): SWOG S1937—Updated design.

Authors: Sadeghi, Sarmad, Callis, Samuel, Lara Jr., Primo N, Berg, Stephanie A., Brown, Jason Robert, Bangs, Rick, Nakagawa, Darrell, Daneshmand, Siamak, Ian Murchie, Thompson, Thomas W., Petrylak, Daniel P., Lerner, Seth P.

Source: Journal of Clinical Oncology; 2/20/2025 Supplement 5, Vol. 43, pTPS887-TPS887, 242p

Future Directions in Bladder Cancer Treatment and Research—The Patient Advocates’ Perspective

Authors: Bangs, Rick, Quale, Diane Zipursky

Source: In Hematology/Oncology Clinics of North America June 2021 35(3):655-664

Bladder cancer patient and provider perspectives on smoking cessation

Authors: Mossanen, Matthew, Smith, Angela B., Onochie, Nnamdi, Matulewicz, Richard, Bjurlin, Marc A., Kibel, Adam S., Abbas, Muhammad, Shore, Neal, Chisolm, Stephanie, Bangs, Rick, Cooper, Zara, Gore, John L.

Source: In Urologic Oncology: Seminars and Original Investigations November 2023 41(11):457-457

From the other side: The patient perspective on cancer clinical trials

Authors: Bangs, Rick, Crispino, Tony

Source: In Urologic Oncology: Seminars and Original Investigations May 2019 37(5):331-335

Eligibility and Endpoints for Clinical Trials in Trimodality Therapy for Bladder Cancer

Authors: Singh, Parminder, Ballas, Leslie, Sonpavde, Guru P., Chen, Ronald C., Bangs, Rick, Bauman, Brian C., Nagar, Himanshu, Delacroix, Scott E., Lerner, Seth P., Efstathiou, Jason A.

Source: Bladder Cancer; October 2024, Vol. 10 Issue: 3 p199-213, 15p

Interventions addressing health-related social needs among patients with cancer.

Authors: Graboyes, Evan M, Lee, Simon C, Lindau, Stacy Tessler, Adams, Alyce S, Adjei, Brenda A, Brown, Mary, Sadigh, Gelareh, Incudine, Andrea, Carlos, Ruth C, Ramsey, Scott D, Bangs, Rick

Source: JNCI: Journal of the National Cancer Institute; Apr2024, Vol. 116 Issue 4, p497-505, 9p

Subject Terms: CANCER patients, EVIDENCE gaps, CLINICAL trials, CANCER treatment, MEETING planning, CANCER patient care

Company/Entity: NATIONAL Academy of Sciences (U.S.)

Patient‐centered prioritization of bladder cancer research

Authors: Smith, Angela B., Chisolm, Stephanie, Deal, Allison, Spangler, Alejandra, Quale, Diane Z., Bangs, Rick, Jones, J. Michael, Gore, John L.

Source: Cancer. 124(15):3136-3144

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100125444048.0x000001&indx=1&recIds=ETOCvdc_100125444048.0x000001

A New Framework for Patient Engagement in Cancer Clinical Trials Cooperative Group Studies

Authors: Deverka, Patricia A, Bangs, Rick, Kreizenbeck, Karma, Delaney, Deborah M, Hershman, Dawn L, Blanke, Charles D, Ramsey, Scott D

Source: Journal of the National Cancer Institute. 110(6):553-559

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100094730224.0x000001&indx=1&recIds=ETOCvdc_100094730224.0x000001

Correlation of urinary comprehensive genomic profile with risk of recurrence of BCG-unresponsive non-muscle invasive bladder cancer treated with atezolizumab in SWOG S1605.

Authors: St-Laurent, Marie-Pier, Plets, Melissa, Black, Peter C., Singh, Parminder, McConkey, David James, Lucia, Scott, Koshkin, Vadim S, Stratton, Kelly Lynn, Bivalacqua, Trinity, Kassouf, Wassim, Porten, Sima P., Bangs, Rick, Tangen, Catherine, Thompson, Ian M., Meeks, Joshua J, Caruso, Vincent M., Phillips, Kevin G., Bicocca, Vincent T., Levin, Trevor G., Lerner, Seth P.

Source: Journal of Clinical Oncology; 2024 Supplement 4, Vol. 42, p529-529, 193p

Randomized phase II trial of gemcitabine, avelumab and carboplatin versus no neoadjuvant therapy preceding surgery for cisplatin-ineligible muscle-invasive urothelial carcinoma (MIUC): SWOG GAP trial (S2011).

Authors: Sonpavde, Guru P., Plets, Melissa, Liss, Michael A., Meeks, Joshua J, Petrylak, Daniel P., Cole, Suzanne, McKay, Rana R., Gupta, Shilpa, Hita, Sandi, Pereira, Taj, Bangs, Rick, Tangen, Catherine, Thompson, Ian Murchie, Lerner, Seth P.

Source: Journal of clinical oncology. 40(6 suppl):TPS591-TPS591

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100152998613.0x000001&indx=1&recIds=ETOCvdc_100152998613.0x000001

SWOG S1314: A randomized phase II study of co-expression extrapolation (COXEN) with neoadjuvant chemotherapy for localized, muscle-invasive bladder cancer with overall survival follow up.

Authors: Flaig, Thomas W., Tangen, Catherine, Daneshmand, Siamak, Alva, Ajjai Shivaram, Lucia, M. Scott, McConkey, David, Theodorescu, Dan, Goldkorn, Amir, Milowsky, Matthew I., Bangs, Rick, MacVicar, Gary R., Bastos, Bruno R., Fowles, Jared, Gustafson, Daniel, Plets, Melissa, Thompson, Ian Murchie, Lerner, Seth P.

Source: Journal of clinical oncology. 40(6 suppl):536-536

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100152996874.0x000001&indx=1&recIds=ETOCvdc_100152996874.0x000001

Advancing Clinical Trial Design for Non-Muscle Invasive Bladder Cancer

Authors: Chang, Elaine, Hahn, Noah M., Lerner, Seth P., Fallah, Jaleh, Agrawal, Sundeep, Kamat, Ashish M., Bhatnagar, Vishal, Svatek, Robert S., Jaigirdar, Adnan A., Bross, Peter, Shore, Neal, Kates, Max, Sachse, Karen, Brewer, Jamie R., O’Donnell, Michael A., Steinberg, Gary D., Viviano, Charles J., Bloomquist, Erik, Ribal, Maria J., Galsky, Matthew D., Oliver, Richard, Black, Peter C., Al-Ahmadie, Hikmat, Brothers, Kenneth, Pohar, Kamal, Dinney, Colin P., Feng, Zhou, Downs, Tracy M., Porten, Sima P., Smith, Angela B., Bangs, Rick, Psutka, Sarah P., Agarwal, Neeraj, Amiri-Kordestani, Laleh, Suzman, Daniel L., Pazdur, Richard, Kluetz, Paul G., Weinstock, Chana

Source: Bladder Cancer; September 2023, Vol. 9 Issue: 3 p271-286, 16p

Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT #02844816).

Authors: Black, Peter C., Tangen, Catherine, Singh, Parminder, McConkey, David James, Lucia, Scott, Lowrance, William Thomas, Koshkin, Vadim S, Stratton, Kelly Lynn, Bivalacqua, Trinity, Kassouf, Wassim, Porten, Sima P., Bangs, Rick, Plets, Melissa, Lerner, Seth P., Thompson, Ian Murchie

Source: Journal of clinical oncology. 39(15 suppl):4541-4541

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100173202190.0x000001&indx=1&recIds=ETOCvdc_100173202190.0x000001

Creating a Checklist for Communicating With Bladder Cancer Patients.

Authors: Bangs, Rick¹

Source: AUANews. Apr2023, Vol. 28 Issue 4, p115-115. 1/2p.

Subject Terms: *BLADDER cancer, *CANCER patients, *PATIENTS' attitudes, *CANCER invasiveness

AUA Patient Perspectives Program.

Authors: Bangs, Rick¹

Source: AUANews. Mar2023, Vol. 28 Issue 3, p27-27. 1p.

Subject Terms: *PATIENTS' attitudes, *SARS-CoV-2 Delta variant, *PATIENT participation, *PATIENT preferences, *EDITING software